Philips, Ypsomed pair up on cloud-connected delivery devices for RA, MS and diabetes

The Switzerland-based Ypsomed Group supplies pens, autoinjectors and infusion hardware to pharmaceutical companies, as well as directly to patients for at-home use. (Philips)

Royal Philips plans to team up with Ypsomed to install digital, self-medication adherence tracking across a line of connected liquid drug delivery devices, including injection and infusion systems used in diabetes, multiple sclerosis and rheumatoid arthritis.

The two companies signed a memorandum of understanding to build out Ypsomed’s new SmartServices platform, based on Philips’ cloud-based HealthSuite, to offer value-added products to the industry and extend Ypsomed’s medical device business.

The Switzerland-based Ypsomed Group supplies pens, autoinjectors and infusion hardware to pharmaceutical companies, as well as directly to patients for at-home use. The companies aim to sign a definitive agreement before the end of the year.

WEBINAR

Webinar: Meet the Challenge of Complex Protein Expression

As market demand continues to rise for more potent and effective therapeutics, biologic pipelines are evolving from standard antibody formats to next-generation biologics (NGBs). In this webinar we will discuss and demonstrate application through case studies, two significant enhancements to Lonza’s GS Xceed® expression system to help address the challenges of NGBs.

“Our partnership with Philips aims at embedding smart devices in a digital health ecosystem that simplifies access to therapy-relevant medication adherence data,” said Ulrike Bauer, senior VP at Ypsomed Delivery Systems.

RELATED: Philips inks 11-year deal for patient monitoring as a service

“This will allow our pharmaceutical customers to focus on building therapy-specific digital solutions for patients, caregivers and physicians,” Bauer said.

“It will shorten time-to-market, enable them to scale-up solutions in a secure HIPAA-compliant way, and allow them to integrate data from Ypsomed devices with other data sources to support many different value-added use cases,” added Dale Wiggins, business leader for the HealthSuite platform at Philips.

Ypsomed’s portfolio includes the consumer-focused mylife Diabetescare brand, as well as YDS Ypsomed Delivery Systems for business-to-business sales.

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.